Edesa Biotech to receive up to CAD $23 Million in funding from Federal Government

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Edesa Biotech, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to CAD $23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company’s first-in-class therapeutic candidate.

Edesa is an alumnus of our WiHI program.

Arsheen Kaur
Previous

Enhanced Medical Nutrition over-subscribes pre-series A financing, announces strategic investment from dsm-firmenich
Next

A made-in-Ontario medical device proven to save lives now being evaluated in its home province